GlassScriptPhysician profile
Sharareh Saadat
NPI 1609036268
$14,615.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $785 · 2021: $73.14 · 2022: $26.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $9,714.46 | 2019-2020 | |
| Abbott Laboratories | $3,633.26 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $304.18 | 2019 | |
| Opko Pharmaceuticals, LLC | $211.77 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $185.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $179.79 | 2019 | |
| Akebia Therapeutics INC | $137.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $87.71 | 2019 | |
| Horizon Therapeutics Plc | $63.41 | 2019-2020 | |
| Shire North American Group INC | $42.50 | 2019 | |
| Nxstage Medical, INC. | $32.65 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.37 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharareh Saadat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.